AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
Public ClinicalTrials.gov record NCT01281254. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS) The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to placebo plus PLD in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.
Study identification
- NCT ID
- NCT01281254
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 223 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2011 (Actual)
- Primary completion
- Aug 29, 2014 (Actual)
- Completion
- Apr 19, 2017 (Actual)
- Last update posted
- Dec 2, 2017
2011 – 2017
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90027 | — |
| Research Site | San Francisco | California | 94143 | — |
| Research Site | Norwalk | Connecticut | 06856 | — |
| Research Site | Stamford | Connecticut | 06902 | — |
| Research Site | Orlando | Florida | 32806 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Evanston | Illinois | 60201 | — |
| Research Site | Saint Louis Park | Minnesota | 55426 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | Asheville | North Carolina | 28806 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Bismarck | North Dakota | 58501 | — |
| Research Site | Abington | Pennsylvania | 19001 | — |
| Research Site | Sioux Falls | South Dakota | 57104 | — |
| Research Site | Fort Sam Houston | Texas | 78234 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Annandale | Virginia | 22003 | — |
| Research Site | Green Bay | Wisconsin | 54301 | — |
| Research Site | Milwaukee | Wisconsin | 53215 | — |
| Research Site | West Allis | Wisconsin | 53227 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01281254, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2017 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01281254 live on ClinicalTrials.gov.